Novo Nordisk introduces Wegovy GLP-1 drug in pill form. Amazon enters the market, offering competitive pricing and convenience for customers. Pharmaceutical giants Eli Lilly and Novo Nordisk face off in the GLP-1 space, while Amazon competes with Hims & Hers, WW International, and GoodRx.

Novo Nordisk leads with the first pill version of Wegovy in 2026, aiming to capture market share. Amazon offers Wegovy at competitive prices, potentially as low as $25 with insurance. Other sellers like Hims & Hers, WW International, and GoodRx will need to match prices to stay competitive.

Amazon’s large customer base gives it an advantage in selling GLP-1 pills. With about 200 million Prime members, Amazon could dominate retail sales. Competitors may struggle to keep up, especially if GLP-1 pills become widely adopted for weight loss. Investors may want to consider Amazon’s potential growth in this market.

Read more at Nasdaq: Amazon Is Now Offering Novo Nordisk’s Wegovy Pill in Its Pharmacy. Here’s How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.